Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines

Characterization of Bioaerosols from Dairy Barns: Reconstructing the Puzzle of Occupational Respiratory Diseases by Using Molecular Approaches

“…As an example, our team discovered high concentrations of archaea in swine barn bioaerosols (33), revealing for the first time a human exposure to archaea through the airborne route. Those archaea (8) and their subcomponents (36) were revealed to have a significant immunogenic potential. Molecular biology is the most efficient approach allowing the evaluation of exposure to archaea and any other nonculturable microorganisms that can have an immunogenic effect on human health (6,11,26,33).…”

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

“…Here, we focus on a recent archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) technology for mucosal vaccines. [39][40][41] The polar membrane lipids in species of the Domain Archaea are uniquely distinct from the ester lipids (unbranched fatty acyl chains, usually unsaturated, attached at sn-1,2 glycerol carbon positions via ester bonds). Archaeal polar lipids comprise of regularly branched, 5-carbon repeating units making up the usually fully saturated (with few exceptions) isopranoid chains which are attached via ether bonds to the sn-2,3 carbons of the glycerol backbone.…”

“…40,41 We use the term "archaeal lipid mucosal vaccine adjuvant and delivery" or the "AMVAD" acronym, to describe these structures. Unlike cochleates which are cylindrical, rolled up bilayer sheets devoid of any internal aqueous space(s), 31,36,49 AMVAD structures do contain aqueous capture volume.…”

“…40 We recently evaluated the potential of the AMVAD system as a mucosal adjuvant and vaccine delivery system. 41 Intranasal immunization of mice with ovalbumin (OVA) formulated in AMVAD structures prepared from the total polar lipids (TPL) extract of Methanobrevibacter smithii (OVA/ AMVAD) elicited strong anti-OVA IgA responses at both local (nasal) and distal (gastrointestinal, vaginal) sites, and in sera. 41 Additionally, robust, antigen-specific systemic antibody (serum IgG1 and IgG2a) and CD8 + CTL responses were also generated.…”

“…41 Intranasal immunization of mice with ovalbumin (OVA) formulated in AMVAD structures prepared from the total polar lipids (TPL) extract of Methanobrevibacter smithii (OVA/ AMVAD) elicited strong anti-OVA IgA responses at both local (nasal) and distal (gastrointestinal, vaginal) sites, and in sera. 41 Additionally, robust, antigen-specific systemic antibody (serum IgG1 and IgG2a) and CD8 + CTL responses were also generated. 41 The primary mucosal and systemic responses elicited were generally well sustained over time (up to 8 months), and exhibited strong memory boost responses.…”